Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG.

Gastroenterology. 2010 Jul;139(1):120-9.e18. doi: 10.1053/j.gastro.2010.04.013.

PMID:
20399780
2.

The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection.

Pearlman BL.

Curr Gastroenterol Rep. 2011 Feb;13(1):78-86. doi: 10.1007/s11894-010-0161-9. Review. Erratum in: Curr Gastroenterol Rep. 2011 Apr;13(2):202-3.

PMID:
21080244
3.

Treatment predictors of a sustained virologic response in hepatitis B and C.

Kau A, Vermehren J, Sarrazin C.

J Hepatol. 2008 Oct;49(4):634-51. doi: 10.1016/j.jhep.2008.07.013. Review.

4.

IL28B single nucleotide polymorphisms in the treatment of hepatitis C.

Lange CM, Zeuzem S.

J Hepatol. 2011 Sep;55(3):692-701. doi: 10.1016/j.jhep.2011.03.006. Review.

5.

Treatment of non-genotype 1 hepatitis C virus patients.

Mangia A, Mottola L.

Curr Gastroenterol Rep. 2012 Feb;14(1):87-93. doi: 10.1007/s11894-011-0235-3. Review.

PMID:
22113745
7.

Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection.

Holmes JA, Desmond PV, Thompson AJ.

Clin Liver Dis. 2011 Aug;15(3):497-513. doi: 10.1016/j.cld.2011.05.009. Review.

PMID:
21867933
8.

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.

Ahlenstiel G, Booth DR, George J.

J Gastroenterol. 2010 Sep;45(9):903-10. doi: 10.1007/s00535-010-0287-4. Review.

PMID:
20635099
9.

Hepatitis C virus infection and genetic susceptibility to therapy.

Sibbing B, Nattermann J.

J Gastrointestin Liver Dis. 2011 Dec;20(4):397-406. Review.

10.

[Role of IL-28B SNPs in the treatment and prognosis of HCV infection].

Tao J, Liu J, Ben KL.

Zhonghua Gan Zang Bing Za Zhi. 2011 Apr;19(4):316-7. Review. Chinese. No abstract available.

PMID:
21805746
11.

A 2015 roadmap for the management of hepatitis C virus infections in Asia.

Lim SG, Dan YY.

Korean J Intern Med. 2015 Jul;30(4):423-33. doi: 10.3904/kjim.2015.30.4.423. Review.

12.
13.

Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.

Cariani E, Villa E, Rota C, Critelli R, Trenti T.

Clin Chem Lab Med. 2011 Aug;49(8):1247-56. doi: 10.1515/CCLM.2011.618. Review.

PMID:
21612542
14.

[Significance of allelic variants of interleukin-28B gene in chronic hepatitis C].

Tikhonova NIu, Burnevich ÉZ, Krasnova TN.

Ter Arkh. 2013;85(12):106-13. Review. Russian.

PMID:
24640679
15.

Host genetic basis for hepatitis C virus clearance: a role for blood collection centers.

Selvarajah S, Tobler LH, Simmons G, Busch MP.

Curr Opin Hematol. 2010 Nov;17(6):550-7. doi: 10.1097/MOH.0b013e32833e7544. Review.

16.

Innate immunity: a new chapter for hepatitis C.

Hydes T, Khakoo SI.

Ann Gastroenterol. 2012;25(3):232-240. Review.

Items per page

Supplemental Content

Support Center